News
HIV, CVS Health and Gilead
Digest more
StockStory.org on MSN1d
Why Gilead Sciences (GILD) Shares Are Sliding Today
Shares of biopharmaceutical company Gilead Sciences (NASDAQ:GILD) fell 3.5% in the morning session after reports that CVS Health will not be adding the company's new HIV prevention drug, Yeztugo, to ...
CVS Health will not add Gilead Sciences' new HIV prevention drug to its commercial plans for now, despite the medicine's ...
CVS Health Corp., one of the largest U.S. managers of drug benefits, said it would give preferred status to the hepatitis C treatments from Gilead Sciences and cover a new competing treatment from ...
CVS’s expansion into primary care is expected to drive long-term growth, while Gilead’s strong pipeline and market position in virology and oncology support its continued dividend growth.
Results that may be inaccessible to you are currently showing.
Hide inaccessible results
Feedback